Ohio State University Comprehensive Cancer Center

James Cancer Hospital and Solove Research Institute

Columbus, OH

Sorting 14 by

Not yet accepting

CARTITUDE-2

Phase 2, Open-Label Study Evaluating the Use of an Investigational CAR-T Cell therapy in Participants with Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • Phase 2

Accepting patients

QUINTESSENTIAL

Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

MonumenTAL-3

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Learn more
  • Bispecific Antibody
  • GPRC5D
  • Randomization
  • Phase 3

Accepting patients

DRAMMATIC

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration (DRAMMATIC)
Learn more
  • Monoclonal Antibody
  • CD38
  • Maintenance
  • Phase 3

Accepting patients

CARTITUDE-6

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more
  • Autologous Stem Cell Transplant
  • CAR T Cell
  • BCMA
  • Phase 3

Accepting patients

Linvoseltamab

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Learn more
  • Bispecific Antibody
  • BCMA
  • Phase 1

Accepting patients

Isatuximab in Frail Patients

Isatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Learn more
  • Monoclonal Antibody
  • CD38
  • Phase 2

Accepting patients

BGB-11417

A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations With Dexamethasone and Carfilzomib in Multiple Myeloma
Learn more
  • BCL-2 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Investigational Cord Blood Units

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation
Learn more
  • Allogeneic Stem Cell Transplant
  • Cord Blood
  • Phase 2

Not yet accepting

COMMANDER

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (COMMANDER)
Learn more
  • CELMoD
  • Monoclonal Antibody
  • CD38
  • Phase 1/2
2 hidden based on your filters. Show All